Phaseline

Companies › InThera Inc. Korea

InThera Inc. Korea: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INT101
Norovirus multivalent antigen vaccine (GII.3, GII.4, GII.17)
–Phase 1Norovirus InfectionsAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07818629INT101Phase 1Norovirus InfectionsInfectious diseaseAug 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.